⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Official Title: First-in-human, Dose Titration and Expansion Trial to Evaluate Safety, Immunogenicity and Preliminary Efficacy of W_pro1 (BNT112) Monotherapy and in Combination With Cemiplimab in Patients With Prostate Cancer

Study ID: NCT04382898

Conditions

Prostate Cancer

Interventions

BNT112
Cemiplimab

Study Description

Brief Summary: Open-label, multicenter, dose titration and four-arm expansion trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of BNT112 cancer vaccine (BNT112) monotherapy or in combination with cemiplimab in patients with metastatic castration resistant prostate cancer (mCRPC: Part 1 and Part 2 Arms 1A and 1B) and in patients with high-risk, localized prostate cancer (LPC). As of February 2023, the trial will be only recruiting LPC patients and no longer mCRPC patients.

Detailed Description: * BNT112 consists of messenger ribonucleic acid (mRNA \[or RNA\]) targeting 5 antigens expressed in de novo and metastatic prostate cancer that are separately complexed with liposomes to form serum-stable RNA lipoplexes (RNA-LPX). * The RNA molecules are immune-pharmacologically optimized for high stability, translational efficiency and presentation on major histocompatibility complex (MHC) class I and II molecules. The vaccine is intended for intravenous (IV) bolus injection. * The RNA-LPX cancer vaccine induces activation of both the adaptive immune system (vaccine antigen-specific CD8+/CD4+ T cell) as well as the innate immune system (TLR7 agonism of single-stranded RNA). The physiology of efficient induction, expansion and differentiation of antigen-specific T cells is associated with programmed death receptor-1 (PD-1) upregulation on these T cells. Thus, the cancer vaccine is expected to have a synergistic mechanism of action with anti-PD-1. * In summary, the mechanism of action of BNT112 both in monotherapy and in combination with anti-PD-1 immune checkpoint inhibitor cemiplimab, together with carefully selected and refined clinical setting presents a unique opportunity for patients with different stages of prostate cancer.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: MALE

Healthy Volunteers: No

Locations

The University of Arizona Cancer Center, Tucson, Arizona, United States

University of Miami Hospital & Clinics /Sylvester Comprehensive Cancer Center, Miami, Florida, United States

University of Pittsburgh Cancer Inst., Pittsburgh, Pennsylvania, United States

Urology San Antonio P.A., San Antonio, Texas, United States

University of Virginia Cancer Center, Charlottesville, Virginia, United States

Universitätsklinikum Bonn, Bonn, , Germany

Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, , Germany

Universitätsklinikum Münster, Münster, , Germany

Studienpraxis Urologie, Nürtingen, , Germany

Urologische Klinik Planegg, Planegg, , Germany

Universitätsklinikum Tübingen, Tübingen, , Germany

Magyar Honvédség Egészségügyi Központ (MH EK Honvédkórház), Budapest, , Hungary

Semmelweis Egyetem, Belgyógyászati Klinika, Budapest, , Hungary

Onkológiai Klinika, Debrecen, , Hungary

Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház, Nyíregyháza, , Hungary

Szent Borbála Kórház, Tatabánya, , Hungary

Cancer Research UK Cambridge Centre, Cambridge, , United Kingdom

Velindre Cancer Centre (VCC), Cardiff, , United Kingdom

University of Glasgow, Beatson WoS Cancer Centre, Glasgow, , United Kingdom

University College London Hospitals, London, , United Kingdom

The Royal Marsden Hospital, London, , United Kingdom

University Hospital Southampton - Southampton General Hospital, Southampton, , United Kingdom

Contact Details

Name: BioNTech Responsible Person

Affiliation: BioNTech SE

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: